Abstract
Recent reports showed BCL11A may be causatively involved in myeloid leukemia. This study investigated the relationship between BCL11A expression levels and adult acute myeloid leukemia patient characteristics as well as clinical outcomes. RT-PCR was employed to detect BCL11A gene expression levels in 80 patients with acute myeloid leukemia. Median BCL11A expression levels of 80 AML bone marrow samples were found to be higher than the control group (0.039 vs. 0.014, p < 0.005). Patients with low BCL11A expression levels had a significantly higher CR (complete remission) rate compared with patients with high BCL11A expression levels (90% vs. 53%, p < 0.005). Moreover, the median OS (overall survival) in patients with low BCL11A expression (268 d) was also longer than that in patients with high BCL11A expression (101.5 d) (p < 0.05). No significant difference was observed between the high and low BCL11A groups with respect to white blood cells, haemoglobin, platelet count, French-American-Britain (FAB) subtypes, percentage of blasts in bone marrow, peripheral blood, cytogenetic risk groups, and CD34 expression. Adult acute myeloid leukemia had a higher BCL11A expression level. High BCL11A expression level was correlated with lower CR rate and shorter OS, suggesting that BCL11A expression could potentially be used as a prognosis indicator.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
